Stereotaxis, Inc. (STXS)

NYSEAMERICAN: STXS · Real-Time Price · USD
2.700
+0.040 (1.50%)
At close: Aug 13, 2025, 4:00 PM
2.660
-0.040 (-1.48%)
After-hours: Aug 13, 2025, 4:48 PM EDT
1.50%
Market Cap 249.07M
Revenue (ttm) 31.81M
Net Income (ttm) -24.64M
Shares Out 92.25M
EPS (ttm) -0.29
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 699,915
Open 2.680
Previous Close 2.660
Day's Range 2.614 - 2.710
52-Week Range 1.540 - 2.716
Beta 1.51
Analysts n/a
Price Target n/a
Earnings Date Aug 7, 2025

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. The company offers robotic magnetic navigation (RMN) systems, such as the Genesis RMN, which enable physicians to complete interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites; and GenesisX RMN, which is designed to enhance the accessibility of RMN by eliminat... [Read more]

Sector Healthcare
IPO Date Aug 12, 2004
Employees 139
Stock Exchange NYSEAMERICAN
Ticker Symbol STXS
Full Company Profile

Financial Performance

In 2024, Stereotaxis's revenue was $26.92 million, an increase of 0.55% compared to the previous year's $26.77 million. Losses were -$25.35 million, 14.9% more than in 2023.

Financial Statements

News

Stereotaxis, Inc. (STXS) Q2 2025 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants David Leo Fischel - CEO & Chairman Kimberly R. Peery - Chief Financial Officer Conference...

5 days ago - Seeking Alpha

Stereotaxis Reports 2025 Second Quarter Financial Results

ST. LOUIS, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resul...

6 days ago - GlobeNewsWire

Stereotaxis Receives U.S. FDA Clearance for MAGiC Sweep Catheter

ST. LOUIS, July 28, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it has re...

16 days ago - GlobeNewsWire

Stereotaxis to Report Second Quarter 2025 Financial Results on August 7, 2025

ST. LOUIS, July 23, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

21 days ago - GlobeNewsWire

Stereotaxis Announces $12.5 Million Registered Direct Offering of Common Stock

ST. LOUIS, July 17, 2025 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has e...

27 days ago - GlobeNewsWire

Stereotaxis: Recurring Revenue Inflection

I rate Stereotaxis Strong Buy, with 85% upside to $4 PT, driven by underappreciated recurring revenue and regulatory catalysts. Recurring revenue is inflecting above 25% growth, with high-margin dispo...

5 weeks ago - Seeking Alpha

First Clinical Results from MAGiC Catheter Study Published in the Journal of Interventional Cardiac Electrophysiology

ST. LOUIS, July 01, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced the publicatio...

6 weeks ago - GlobeNewsWire

Stereotaxis, Inc. (STXS) Q1 2025 Earnings Call Transcript

Stereotaxis, Inc. (NYSE:STXS) Q1 2025 Earnings Conference Call May 12, 2025 4:30 PM ET Company Participants David Fischel - Chairman and CEO Kim Peery - Chief Financial Officer Conference Call Partic...

3 months ago - Seeking Alpha

Stereotaxis Reports 2025 First Quarter Financial Results

ST. LOUIS, May 12, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial result...

3 months ago - GlobeNewsWire

Stereotaxis to Report First Quarter 2025 Financial Results on May 12, 2025

ST. LOUIS, April 22, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will ...

4 months ago - GlobeNewsWire

Stereotaxis to Feature First-Ever Live Demo of GenesisX Robotic System at HRS 2025

ST. LOUIS, April 21, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, announced today it will host ...

4 months ago - GlobeNewsWire

Stereotaxis Highlighted by NVIDIA at GTC Artificial Intelligence Conference and Accepted into NVIDIA Connect Program

ST. LOUIS, March 19, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that NVIDIA h...

5 months ago - GlobeNewsWire

Stereotaxis to Present at 37th Annual Roth Conference

ST. LOUIS, March 10, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fi...

5 months ago - GlobeNewsWire

Stereotaxis To Get FDA Approval Of MAGiC This Fall, Ending Cash Burn

I addressed the bearish concerns some investors have. Management's conservative 2025 sales guidance set beatable targets, focusing on the existing system backlog and MAGiC usage in Europe. MAGiC Sweep...

5 months ago - Seeking Alpha

Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript

Stereotaxis, Inc. (STXS) Q4 2024 Earnings Call Transcript

5 months ago - Seeking Alpha

Stereotaxis Submits EMAGIN Catheter for Regulatory Clearance as it Pioneers Robotics for Endovascular Surgery

ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulator...

5 months ago - GlobeNewsWire

Stereotaxis Submits First Ever Robotically Navigated High-Density EP Mapping Catheter for Regulatory Clearance

ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced FDA regulator...

5 months ago - GlobeNewsWire

Stereotaxis Reports 2024 Full Year Financial Results

ST. LOUIS, March 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported financial resu...

5 months ago - GlobeNewsWire

Stereotaxis to Present at 45th Annual TD Cowen Healthcare Conference

ST. LOUIS, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that David Fis...

6 months ago - GlobeNewsWire

Stock Market Sleeps On Stereotaxis MAGiC CE Mark

Stereotaxis' MAGiC catheter received CE Mark approval in Europe, enabling the company to earn an additional $3k per procedure with +80% gross margins. FDA approval of MAGiC is expected by September. T...

6 months ago - Seeking Alpha

Stereotaxis to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

ST. LOUIS, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will r...

6 months ago - GlobeNewsWire

Stereotaxis Announces First GenesisX Robotic System Order

ST. LOUIS, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it has receive...

6 months ago - GlobeNewsWire

Stereotaxis Receives CE Mark Approval for the MAGiC Ablation Catheter

ST. LOUIS, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it receiv...

7 months ago - GlobeNewsWire

Oulu University Hospital Enhances Leadership in Arrhythmia Care with Advanced Genesis Robotic Technology

ST. LOUIS, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that physician...

7 months ago - GlobeNewsWire

Magbot Robotic Magnetic Navigation Ablation Catheter Approved by China's NMPA

ST. LOUIS and SHANGHAI, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS) and Shanghai MicroPort EP Medtech Co., Ltd. (688351.SH, “MicroPort EP”), today announced that the Magbot™ Magnetic Na...

8 months ago - GlobeNewsWire